ACIU · AC Immune SA Common Stock
View on chartInsiders & Stakes
| Andrea Pfeifer Chief Executive Officer | ▼ Sell | Open Market | 3,820,288 Shares held | 5/15/2026 | View profile |
| Roy Ervin Twyman Director | ▲ Buy | Grant | 92,556 Shares held | 6/11/2026 | View profile |
| Monika Buetler Director | ▲ Buy | Grant | 71,656 Shares held | 6/11/2026 | View profile |
| Martin Zuegel Interim CEO | ▲ Buy | Grant | 71,408 Shares held | 6/11/2026 | View profile |
| Carl Howard June Director | ▲ Buy | Grant | 67,556 Shares held | 6/11/2026 | View profile |
| Renee Aguiar-Lucander Director | ▲ Buy | Grant | 51,136 Shares held | 6/11/2026 | View profile |
Transaction History
| Roy Ervin Twyman | ▲ Buy | Grant | 16,568 | $0 | 6/11/2026 |
| Renee Aguiar-Lucander | ▲ Buy | Grant | 16,568 | $0 | 6/11/2026 |
| Martin Zuegel | ▲ Buy | Grant | 33,136 | $0 | 6/11/2026 |
| Monika Buetler | ▲ Buy | Grant | 17,751 | $0 | 6/11/2026 |
| Carl Howard June | ▲ Buy | Grant | 16,568 | $0 | 6/11/2026 |
| Andrea Pfeifer | ▼ Sell | Open Market | 10,000 | $28K | 5/15/2026 |
| Andrea Pfeifer | ▲ Buy | Open Market | 10,000 | $31K | 4/15/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
AC Immune Parkinson’s Vaccine Study Meets Safety and Immunogenicity Goals
AC Immune’s Parkinson’s vaccine study reached its safety and immunogenicity targets, a key milestone for the company’s pipeline. The company also reported ongoing progress in its ACI-7104 program and other pipeline expansions. This development comes as the stock trades near its 52‑week low, with a support level at $2.76.
AC Immune Parkinson’s Vaccine Study Meets Safety and Immunogenicity Goals. AC Immune’s Parkinson’s vaccine study reached its safety and immunogenicity targets, a key milestone for the company’s pipeline. The company also reported ongoing progress in its ACI-7104 program and other pipeline expansions. This development comes as the stock trades near its 52‑week low, with a support level at $2.76.